The metabolism of olanexidine
[1-(3,4-dichlorobenzyl)-5-octylbiguanide], a new potent biguanide
antiseptic, was investigated in dog liver microsomes to characterize
the enzyme(s) catalyzing the biotransformation of olanexidine to C-C
bond cleavage metabolites. Olanexidine was initially biotransformed to
monohydroxylated metabolite 2-octanol (DM-215), and DM-215 was
subsequently oxidized to diol derivatives
threo-2,3-octandiol (DM-221) and
erythro-2,3-octandiol (DM-222). Diols were further
biotransformed to a ketol derivative and C-C bond cleavage metabolite
(DM-210, hexanoic acid derivative), an in vivo end product, in the
incubation with dog liver microsomes. The formations of DM-215, DM-221,
DM-222, and DM-210 followed Michaelis-Menten kinetics, and
Eadie-Hofstee analysis of the metabolite formation activity confirmed
single-enzyme Michaelis-Menten kinetics. The
Km and Vmax
values for the formation of DM-210 appeared to be 2.42 µM and 26.6 pmol/min/mg in the oxidation of DM-221 and 2.48 µM and 30.2 pmol/min/mg in the oxidation of DM-222. The intrinsic clearance
(Vmax/Km) of the
C-C bond cleavage reactions was essentially the same with either DM-221
or DM-222 as substrate. These oxidative reactions were significantly
inhibited by quinidine, a selective inhibitor of CYP2D subfamilies,
indicating the metabolic C-C bond cleavage of the octyl side chain of
olanexidine to likely be mediated via the CYP2D subfamily in dog liver
microsomes. This aliphatic C-C bond cleavage by cytochrome P450s may
play an important role in the metabolism of other drugs or endogenous
compounds possessing aliphatic chains.
 |
Introduction |
Olanexidine
monohydrochloride hemihydrate (OPB-2045) is a newly synthesized
antimicrobial agent (Tsubouchi et al., 1997
) that has potent
microbicidal activity toward fungi (yeast), Gram-negative bacteria
(Pseudomonas aeruginosa), and Gram-positive bacteria including methicillin-resistant Staphylococcus aureus
and vancomycin-resistant Enterococci at low concentrations
(Ohguro et al., 1997
; Sakagami et al., 1999
)
The absorption, distribution, metabolism, and excretion of olanexidine
have been reported for rats and dogs after subcutaneous administration
(Kudo et al., 1998a
,b
,c
,d
). Olanexidine is eliminated principally by
metabolism in rats and dogs (Kudo et al., 1998c
,d
), and four
metabolites have been structurally identified in dog urine as
6-[5-(3,4-dichlorobenzyl)-1-biguanidino] hexanoic acid (DM-2101),
4-[5-(3,4-dichlorobenzyl)-1-biguanidino] butanoic acid (DM-212), 5-[5-(3,4-dichlorobenzyl)-1-biguanidino] pentanoic acid (DM-213), and
3,4-dichlorobenzoic acid (Fig. 1) (Kudo
et al., 1998c
). Interestingly, these metabolites, except
3,4-dichlorobenzoic acid, are each a methylene chain shorter with a
carboxy end, and they are predominant metabolites of olanexidine in
both rats (Kudo et al., 1998d
) and dogs (Kudo et al., 1998c
).

View larger version (17K):
[in this window]
[in a new window]
|
Fig. 1.
Presumed metabolic pathways on the formation
of in vivo end products DM-210, DM-212, DM-213, and 3,4-dichlorobenzoic
acid from olanexidine.
Pathways of metabolism are hypothetical and compounds shown in square
brackets were not observed.
|
|
Previous in vitro studies in rat and dog liver preparations
demonstrated the degraded products of olanexidine to be produced by C-C
bond cleavage following sequential oxidative reactions (monohydroxylation, dihydroxylation, and ketol formation at the octyl
side chain, Fig. 1), but not
-oxidation (Umehara et al., 2000
).
These reactions required NADPH as a cofactor, and the C-C bond cleavage
reaction was inhibited by cytochrome P450 inhibitors, indicating
cytochrome P450 as an enzyme possibly involved in the metabolism of
olanexidine (Umehara et al., 2000
).
Some cytochrome P450 enzymes integrated into biosynthetic pathways
possess catalytic activity not only in conventional hydroxylation reactions but also in the C-C bond cleavage reactions (Akhtar et al.,
1993
; Ortiz de Montellano, 1995
). The C-20
C-22 bond of cholesterol is
cleaved by a mitochondrial cytochrome P450 (CYP11A1) (Shikita and Hall,
1974
; Byon and Gut, 1980
; Ortiz de Montellano, 1995
), and removal of
the pregnenolone side chain to produce dehydroisoandrosterone is
mediated by the cytochrome P450 system (CYP17) (Corina et al., 1991
;
Miller et al., 1991
). However, no information is available regarding
the enzyme(s) involved in the C-C bond cleavage reactions in the
metabolism of drugs containing aliphatic chains.
This study was conducted to characterize the enzyme(s) catalyzing the
metabolic conversion of olanexidine into C-C bond cleavage metabolites
using in vitro metabolic intermediates of olanexidine as substrate.
 |
Materials and Methods |
Chemicals.
Olanexidine monohydrochloride hemihydrate, DM-210 dihydrochloride,
8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2-octanol dihydrochloride (DM-215 dihydrochloride),
threo-8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2,3-octandiol dihydrochloride (DM-221 dihydrochloride), and
erythro-8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2,3-octandiol dihydrochloride (DM-222 dihydrochloride) were obtained from Otsuka Pharmaceutical Co., Ltd. (Tokyo, Japan).
-NADPH,
-naphthoflavone, troleandomycin, quinidine, and sulfaphenazole were purchased from Sigma
Chemical Co. (St. Louis, MO). S-Mephenytoin was purchased from Ultrafine Chemical Co. (Manchester, UK). Pentobarbital was purchased from Tokyo Chemical Industry Co., Ltd. (Tokyo, Japan). Sodium
N,N-diethyldithiocarbamate trihydrate was
obtained from Wako Pure Chemical Industries (Osaka, Japan). All other
reagents and solvents were of analytical grade.
Animal Treatments and Preparation of Microsomes.
Three male beagle dogs from Hazleton Research Products Inc.
(Cumberland, VA) were acclimatized in a controlled area maintained at
23 ± 2°C and 60 ± 10% relative humidity during 12-h
light/dark cycles. The animals were fed laboratory chow CD-5 (Japan
Clea Co., Ltd., Tokyo, Japan), and water was available ad libitum
during acclimatization. Dogs 19 to 23 months of age were used in this study. The animals were sacrificed by exsanguination under anesthesia with pentobarbital. The livers were resected and washed with ice-cold saline and homogenized in 3 volume/liver weight of 1.15% KCl solution with a Waring Blender. The homogenate was centrifuged at
9000g for 30 min at 4°C. To prepare liver microsomes, the
9000g supernatant was centrifuged at 105,000g for
60 min at 4°C. The microsomal pellet thus obtained was resuspended in
0.05 M phosphate buffer (pH 7.4), and the microsomes were stored at
80°C. The protein concentration was determined using Bio-Rad DC
protein assay kits (Hercules, CA).
Assay of DM-210 Formation Activity.
The reaction mixtures contained 0.1 M phosphate buffer (pH 7.4), 2.5 mM
-NADPH, DM-221 dihydrochloride, or DM-222 dihydrochloride, and dog
microsomal protein (1 mg) in a final incubation volume of 0.5 ml.
DM-221 dihydrochloride or DM-222 dihydrochloride was dissolved in
methanol. The reaction was initiated by the addition of a cofactor and
was carried out in air at 37°C in a shaking water bath for 30 min.
Under the conditions used, the formation of DM-210 increased linearly
with time (5-30 min) and with protein concentration (0.1-1 mg). In
experiments to determine kinetic parameters for DM-210 formation,
substrate concentrations of 0.25 to 10 µM were studied.
The effects of the following selective CYP inhibitors on the formation
of DM-210 were examined:
-naphthoflavone for CYP1A1/2 (Tassaneeyakul
et al., 1993
), sulfaphenazole for CYP2C8/9 (Back et al., 1988
),
S-mephenytoin for CYP2C19 (Wrighton et al., 1993
), quinidine
for CYP2D6 (Otton et al., 1988
), diethyldithiocarbamate for CYP2E1
(Guengerich et al., 1991
), and troleandomycin for CYP3A (Watkins et
al., 1985
). The concentration of DM-221 dihydrochloride or DM-222
dihydrochloride was 5 µM. The inhibitors were preincubated with dog
liver microsomes and cofactor for 15 min, and the reaction was
initiated by the addition of the substrates. The concentrations of
inhibitors ranged from 1 to 100 µM
For all experiments the reaction was terminated by adding 0.5 ml of
methanol. An aliquot (50 µl) of the supernatant obtained after
centrifugation to pellet the denatured protein was analyzed by HPLC as
described below.
Assay of DM-215 Formation Activity.
The reaction mixtures contained 0.1 M phosphate buffer (pH 7.4), 2.5 mM
-NADPH, olanexidine monohydrochloride hemihydrate, and dog
microsomal protein (0.25 mg) in a final incubation volume of 0.5 ml.
Olanexidine monohydrochloride hemihydrate was dissolved in methanol.
The reaction was initiated by the addition of a cofactor and carried
out in air at 37°C in a shaking water bath for 10 min. Under these
conditions, the reaction rate was linear for at least 20 min at the
enzyme concentration. In experiments to determine the kinetic
parameters for DM-215 formation, substrate concentrations of 2.5 to 75 µM were studied.
To examine the effects of selective CYP inhibitors on the formation of
DM-215, a substrate concentration of 25 µM was selected. The
inhibition studies were performed in the same manner described under
Assay of DM-210 Formation Activity.
Reactions were terminated by adding 0.5 ml of methanol. An aliquot (50 µl) of the supernatant obtained after centrifugation to pellet the
denatured protein was analyzed by HPLC.
Assay of DM-221 or DM-222 Formation Activity.
The reaction mixtures contained 0.1 M phosphate buffer (pH 7.4), 2.5 mM
-NADPH, DM-215 dihydrochloride, and dog microsomal protein (1 mg) in
a final incubation volume of 0.5 ml. DM-215 dihydrochloride was
dissolved in methanol. The reaction was initiated by the addition of a
cofactor and was carried out in air at 37°C in a shaking water bath
for 30 min. Under these conditions, the reaction rate was linear for at
least 60 min at the enzyme concentration. In experiments to determine
the kinetic parameters for DM-221 or DM-222 formation, substrate
concentrations of 5 to 250 µM were studied.
To examine the effects of selective CYP inhibitors on the formation of
DM-221 or DM-222, a substrate concentration of 50 µM was selected.
The inhibition studies were performed in the same manner described
under Assay of DM-210 Formation Activity.
Reactions were terminated by adding 0.5 ml of methanol. An aliquot (50 µl) of the supernatant obtained after centrifugation to form a pellet
from the denatured protein was analyzed by HPLC.
HPLC.
The HPLC system consisted of two model 510 high-pressure HPLC pumps
(Waters Associates, Milford, MA), a model 717 automatic sample
processor (Waters), a model 486 UV detector (Waters), a model 680 automatic gradient controller (Waters), and a model C-R7A Chromatopac
(Shimadzu, Kyoto, Japan).
In the assay for DM-210 production, a TSKgel
ODS-80TS column (4.6-mm i.d. × 250-mm; Tosoh,
Tokyo, Japan) was used at a flow rate of 1 ml/min with UV detection at
240 nm. The mobile phase used was a solution of 30% acetonitrile in
water containing 1% acetic acid. The retention times for DM-221,
DM-222, DM-210, and ketol (M-2) were 9.3, 10.1, 12.1, and 13.6 min,
respectively. The calibration curves of DM-210 and M-2 were established
by an absolute standard method, based on the peak area of DM-210 and M-2. The concentration of M-2 in the incubation was converted to the
equivalent value of unchanged compounds (DM-221 or DM-222) because
there was no authentic standard.
For measurement of DM-215 production, a TSKgel
ODS-80TS column (4.6-mm i.d. × 250-mm; Tosoh)
was used at a flow rate of 1 ml/min with UV detection at 240 nm. The
mobile phase used was a solution of 36% acetonitrile in water
containing 1% acetic acid. The retention time for DM-215 was 10.8 min.
The calibration curve of DM-215 was established by an absolute standard
method, based on the peak area of DM-215.
In the assay for DM-221 or DM-222 production, a TSKgel
ODS-80TM column (4.6-mm i.d. × 150-mm;
Tosoh) was used at a flow rate of 1 ml/min with UV detection at 240 nm.
For the mobile phase, 10% acetonitrile in water containing 0.1%
acetic acid was used as solution A and 80% acetonitrile in water
containing 0.1% acetic acid as solution B. The metabolites were
analyzed using a linear gradient developed from 10 to 35% solution B
over a period of 30 min. The retention times for DM-221 and DM-222 were
17.0 and 18.1 min, respectively. The calibration curves of DM-221 and
DM-222 were established by an absolute standard method, based on the peak height of DM-221 and DM-222.
Characterization of the M-1 and M-2 Metabolites.
The reaction mixture with DM-221 or DM-222 and dog liver microsomes was
extracted by methanol, and the extract was analyzed by liquid
chromatography/electrospray ionization-tandem mass spectrometry (LC/ESI-MS/MS) to characterize the chemical structures of the metabolites.
HPLC analysis was carried out with a Waters HPLC system equipped with a
model 600s controller, a model 616 FHU pump, a model 717P automatic
sample processor, a model 717HC cooler, a model 486 UV Detector, and a
model IL-DEGA in-line degasser. A YMC-Pack Pro C18 column (2.0-mm i.d. × 150-mm; YMC Co., Ltd., Kyoto, Japan) was used at a flow rate of 0.2 ml/min. The metabolites were analyzed using a linear gradient developed
from 0 to 50% solution B over a period of 45 min.
MS/MS analysis was performed using a Finnigan MAT (San Jose, CA)
triple-stage quadrupole TSQ-7000 mass spectrometer equipped with an ESI
source. The interface and mass spectrometer were operated under the
following conditions: ion mode, positive; capillary temperature,
240°C; sheath gas pressure of nitrogen, 70 psi; auxiliary nitrogen
gas flow rate, 10 U; electron multiplier voltage, 1.4 kV; collision gas
of argon, about 2.0 mTorr; and collision energy,
24 eV.
Kinetic Analysis.
The apparent Km and
Vmax values were calculated from a
nonlinear regression analysis with a computer program, WinNonlin
Standard (version 2.1, Scientific Consulting, Inc., Apex, NC).
Graphical analysis of Eadie-Hofstee plots was conducted for liver
microsomal olanexidine oxidation. The intrinsic clearance
(CLintrinsic) was calculated using the following
equation:
CLintrinsic = Vmax/Km.
 |
Results |
DM-210 Formation Activity in Dog Liver Microsomes.
DM-221 or DM-222 was incubated with dog liver microsomes in the
presence of NADPH, and the methanol extract was analyzed by HPLC-UV and
LC/ESI-MS/MS. In the reaction mixture, two metabolites, M-1 and M-2,
were observed (Fig. 2).

View larger version (21K):
[in this window]
[in a new window]
|
Fig. 2.
HPLC chromatogram of the extract obtained
from the incubation mixture of DM-221 (A) or DM-222 (B) with dog liver
microsomes.
DM-221 or DM-222 (10 µM) was incubated at 37°C with dog liver
microsomes in the presence of NADPH (2.5 mM) in 0.1 M phosphate buffer
(pH 7.4) for 30 min. HPLC was performed with methanol extract from the
incubation mixture as described under Materials and
Methods.
|
|
M-1 was identified as DM-210 because the [M + H]+ ion in the precursor ion mass spectrum, the
product ion mass spectrum, and HPLC retention time were essentially the
same as for the authentic standard. M-2 displayed a molecular ion of
m/z 402 [M + H]+ in the
precursor ion mass spectrum, indicating this metabolite to have a
molecular weight of 401, 2 less than that of the unchanged compound. In
addition, the characteristic fragment ions at m/z 218 and 202 were observed in the product mass spectrum (Fig.
3). M-2 would thus appear to be a ketol
derivative of DM-221 or DM-222.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 3.
ESI product ion mass spectrum of [M + H]+ of metabolite M-2 at m/z 402.
LC/ESI-MS/MS conditions are described under Materials and
Methods.
|
|
The formation of DM-210 was consistent with Michaelis-Menten kinetics,
and Eadie-Hofstee plots of DM-210 formation activity demonstrated
monophasic Michaelis-Menten kinetics (Fig.
4). The apparent
Km and Vmax
values for the formation of DM-210 were 2.42 µM and 26.6 pmol/min/mg
in the oxidation of DM-221 and 2.48 µM and 30.2 pmol/min/mg in the
oxidation of DM-222. The intrinsic clearance, calculated as
Vmax/Km, was
11.0 µl/min/mg for DM-221 and 12.2 µl/min/mg for DM-222, indicating
no stereoselectivity in the oxidation of diol derivatives.

View larger version (14K):
[in this window]
[in a new window]
|
Fig. 4.
Eadie-Hofstee plots for the formation of
DM-210 by dog liver microsomes using DM-221 (A) or DM-222 (B) as
substrate.
Each value of triplicate determinations using microsomes obtained from
three different dog livers is shown.
|
|
Selective cytochrome P450 inhibitors were used in this study to
determine the potential roles of cytochrome P450 isoforms on the
metabolism of olanexidine (Fig. 5).
Quinidine, a selective inhibitor of CYP2D subfamilies, inhibited DM-210
formation by approximately 30% at 10 µM.
-Naphthoflavone (an
inhibitor of CYP1A1/2 subfamilies), sulfaphenazole (an inhibitor of
CYP2C8/9 subfamilies), S-mephenytoin (an inhibitor of the
CYP2C19 subfamily), diethyldithiocarbamate (an inhibitor of the CYP2E1
subfamily), and troleandomycin (an inhibitor of CYP3A subfamilies) had
no inhibitory effect on DM-210 formation activity in male dog liver microsomes. Figure 6 shows the effects of
selective cytochrome P450 inhibitors on the formation of M-2 (ketol).
Quinidine,
-naphthoflavone, sulfaphenazole, and troleandomycin
inhibited M-2 formation.

View larger version (20K):
[in this window]
[in a new window]
|
Fig. 5.
Effects of CYP isoform-selective inhibitors
on the formation of DM-210 in dog liver microsomes.
Data are expressed as means ± S.D. of triplicate determinations
using microsomes obtained from three different dog livers. ND, not
detected.
|
|

View larger version (19K):
[in this window]
[in a new window]
|
Fig. 6.
Effects of CYP isoform-selective inhibitors
on the formation of M-2 in dog liver microsomes.
Data are expressed as means ± S.D. of triplicate determinations
using microsomes obtained from three different dog livers.
|
|
DM-215 Formation Activity in Dog Liver Microsomes.
The biotransformation rate of olanexidine to 2-hydroxylated metabolite
2-octanol (DM-215) by dog liver microsomes was consistent with
Michaelis-Menten kinetics, and Eadie-Hofstee plots of DM-215 formation
activity demonstrated monophasic Michaelis-Menten kinetics (Fig.
7). The apparent
Km and Vmax
values for the formation of DM-215 were 20.8 µM and 737 pmol/min/mg,
respectively. Quinidine, a specific inhibitor of CYP2D subfamilies,
only inhibited the 2-hydroxylation of olanexidine (Table
1). Other CYP-specific inhibitors had no
effect on this reaction.

View larger version (18K):
[in this window]
[in a new window]
|
Fig. 7.
Eadie-Hofstee plot for the formation of
DM-215 by dog liver microsomes.
Each value of triplicate determinations using microsomes obtained from
three different dog livers is shown.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 1
Effects of various inhibitors on DM-215 formation with dog liver
microsomes
Olanexidine was incubated with the microsomes for 10 min at 37°C in
the presence of various inhibitors. Each inhibitor was added to the
incubation mixture at 100 µM, except for -naphthoflavone (1 µM).
Enzyme incubation and metabolite analysis were carried out in
triplicate, and the data were expressed as means ± S.D. Numbers
in parentheses represent the relative activities.
|
|
DM-221 and DM-222 Formation Activity in Dog Liver Microsomes.
The biotransformation rates of DM-215 to diol metabolites
threo-2,3-octandiol (DM-221) and
erythro-2,3-octandiol (DM-222) by dog liver microsomes were
consistent with Michaelis-Menten kinetics, and Eadie-Hofstee plots of
DM-221 or DM-222 formation activity demonstrated monophasic
Michaelis-Menten kinetics (Fig. 8). The
apparent Km and
Vmax values for the formation of DM-221 and
DM-222 were 36.5 µM and 20.8 pmol/min/mg, and 108 µM and 42.3 pmol/min/mg, respectively. Quinidine, a specific inhibitor of CYP2D
subfamilies, only inhibited the hydroxylation of DM-215 (Table
2). Other CYP-specific inhibitors had no
effect on the reaction.

View larger version (15K):
[in this window]
[in a new window]
|
Fig. 8.
Eadie-Hofstee plots for the formation of
DM-221 (A) and DM-222 (B) by dog liver microsomes.
Each value of triplicate determinations using microsomes obtained from
three different dog livers is shown.
|
|
View this table:
[in this window]
[in a new window]
|
TABLE 2
Effects of various inhibitors on DM-221 and DM-222 formation with dog
liver microsomes
DM-215 was incubated with the microsomes for 30 min at 37 °C in the
presence of various inhibitors. Each inhibitor was added to the
incubation mixture at 100 µM, except for -naphthoflavone (1 µM).
Enzyme incubation and metabolite analysis were carried out in
triplicate, and the data were expressed as means ± S.D. Numbers
in parentheses represent the relative activities.
|
|
 |
Discussion |
DM-210, a major metabolite of olanexidine, is produced via C-C
bond cleavage following sequential oxidative reactions, but not
-oxidation, with possible involvement of cytochrome P450 systems
(Umehara et al., 2000
). However, there is no information identifying
the enzyme(s) involved in the C-C bond cleavage of olanexidine or the
kinetics of metabolism. Characterizing the enzymes catalyzing
olanexidine metabolism should contribute to clarification of the roles
and mechanism of oxidative C-C bond cleavage by cytochrome P450 in the
metabolism of other drugs or endogenous compounds containing aliphatic
chains. The present study shows the biotransformation of olanexidine to
be catalyzed by male dog liver microsomes and characterizes the
enzyme(s) responsible for C-C bond cleavage reaction.
Olanexidine was initially monohydroxylated to DM-215, which was
subsequently oxidized to diol derivatives (DM-221 or DM-222). Diols
were further biotransformed to a ketol derivative and DM-210 (hexanoic
acid derivative), an in vivo end product, in the incubation with dog
liver microsomes. The formation of DM-215, DM-221, DM-222, and DM-210
was consistent with Michaelis-Menten kinetics. Eadie-Hofstee analysis
of the metabolite formation activity confirmed single-enzyme Michaelis-Menten kinetics, indicating that only one cytochrome P450
isoform is involved in the metabolite formation. The inhibition studies
in dog liver microsomes using CYP isoform-selective inhibitors indicated that these oxidative reactions are likely mediated via the
CYP2D subfamily. Several CYP inhibitors inhibited ketol formation, indicating that cytochrome P450s are also involved in the oxidation of
diols to ketol.
Some cytochrome P450 enzymes integrated into biosynthetic pathways have
catalytic activity not only in conventional hydroxylation reactions but
in C-C bond cleavage reactions, as well (Akhtar et al., 1993
; Ortiz de
Montellano, 1995
). The C-20
C-22 bond of cholesterol is cleaved by a
mitochondrial P450 enzyme (CYP11A1) that catalyzes three sequential
oxidative steps, each consuming one molecule of oxygen and one of NADPH
(Shikita and Hall, 1974
; Byon and Gut, 1980
; Ortiz de Montellano,
1995
). The three steps are 22(R)-hydroxylation,
20(S)-hydroxylation, and severance of the C-20
C-22 bond.
There are two possible mechanisms for the C-20
C-22 bond of
cholesterol scission (Ortiz de Montellano, 1995
). In one, the activated
oxygen complex ([Fe=O]3+) is intercepted by
addition of a hydroxyl group of
20(R),22(R)-dihydroxycholesterol, followed by
proton removal from the hydroxyl adjacent to the resulting hydroperoxide to initiate C-C bond cleavage. In the other mechanism, abstraction of the hydrogen from one of the two side chain hydroxyls by
the activated oxygen complex could produce an alkoxy radical. Homolytic
scission of the C-C bond in this species and electron transfer from the
resulting carbon radical to the protonated iron-oxygen complex
completes the reaction.
The 17
-hydroxylation of pregnenolone (or progesterone) and cleavage
of the C-17
C-20 C-C bond in the 17
-hydroxylated steroid to give
dehydroepiandrosterone (or androstenedione) are catalyzed by CYP17
(Zuber et al., 1986
; Barnes et al., 1991
). Akhtar et al. (1993
, 1994
)
propose that C-C bond cleavage reaction catalyzed by aromatase,
lanosterol 14
-demethylase, and CYP17 occurs through the
participation of the Fe3+-O-OH species produced
as an intermediate in cytochrome P450 reactions and is trapped by the
electrophilicity of the carbonyl compound to afford a peroxide adduct
that fragments with consequent acyl-carbon cleavage.
In the case of olanexidine, the same mechanism involving the
intermediate formation of a ferric peroxide complex
(Fe3+-O-OH) for the bond cleavage catalyzed by
CYP17 may be applicable to C-C bond cleavage of the octyl side chain of
olanexidine, because the carbonyl compound [M-2 (ketol)] was observed
in the reaction mixture in this study (Fig.
9, pathways A and B). Furthermore, the
formation of DM-210 was not changed with inhibition of ketol formation
(Figs. 5 and 6), suggesting that the same two mechanisms involving the
intermediate formation of a high-valent oxoiron complex
([Fe=O]3+) for the bond cleavage catalyzed by
CYP11A1 may be applicable to C-C bond cleavage of the octyl side chain
of olanexidine (Fig. 9, pathways C and D). These oxidative reactions
catalyzed by cytochrome P450s may be considered involved in the
production of DM-212 and DM-213 in vivo.
The CYP2D subfamily is considered to be involved in the metabolism of
the octyl side chain of olanexidine. The presence of some cytochrome
P450s has been reported in dog, and characterization of cytochrome
P450s by amino acid sequence has shown cytochrome P450s belonging to
the CYP1A (Uchida et al., 1990
), CYP2C (Uchida et al., 1990
; Shiraga et
al., 1994
), CYP2D (Sakamoto et al., 1995
), and CYP3A (Ciaccio et al.,
1991
) subfamilies to be present in dog liver. Catalytic activities
using specific probes and inhibitions using specific CYP-isoform
inhibitors have been confirmed in dog (Sakamoto et al., 1995
; Chauret
et al., 1997
). The canine CYP2D subfamily possesses enzymatic
activities similar to human CYP2D6. Furthermore, quinidine and quinine,
which are selective inhibitors of human CYP2D6 and rat CYP2D1,
respectively, are both shown to be inhibitors of the CYP2D
subfamily-catalyzed bufuralol 1'-hydroxylase activity in dog liver
microsomes with nearly equal potency (Roussel et al., 1998
). The
inhibition data in this study using quinidine are consistent with the
proposed metabolism of olanexidine by the CYP2D subfamily. In the CYP2D
subfamily-mediated catalytic reactions, it has been suggested that the
CYP2D subfamily requires ion-pair formation between a substrate and the
enzyme for effective catalytic activity (Smith, 1991
; Smith and Jones,
1992
) and, hypothetically, a positively charged basic nitrogen
(pKa > 7.5) located 5 to 7 Å from the
site of oxidation for typical CYP2D subfamily substrate (Strobl and
Wolff, 1991
). Olanexidine (pKa 2.3 and >12) and
its metabolites (DM-215, DM-221, and DM-222) have two basic nitrogen atoms in the biguanide structure, which is highly ionized at
physiological pH. Therefore, they may be a typical substrate of the
CYP2D subfamily. The stereoselectivity of oxidation is consistent for
almost all CYP2D substrates (Smith and Jones, 1992
). However,
enantioselectivity was not apparent in DM-210 formation by dog liver
microsomes. The apparent Michaelis-Menten constant
Km was found basically the same for the two
enantiomers. The binding affinity of threo- and
erythro-2,3-octandiol to CYP2D subfamily should thus not
differ, and the site of oxidation rather than binding of the substrate may be under stereochemical control (Koymans et al., 1992
).
As with the metabolic pathway of olanexidine, there are compounds whose
metabolites contain side chains, in which odd and even numbers of
carbon fragments have been removed by metabolism. The pentyl side chain
of cannabidiol and its derivatives is reduced to two, three, or four
carbon atoms by removal of even and odd numbers of carbon atoms (Harvey
and Leuschner, 1985
; Harvey, 1989
, 1990
; Samara et al., 1990
). Sinz et
al. (1997)
found CI-976, a specific acyl coenzyme A:cholesterol
acyltransferase inhibitor, to be metabolized to a 5- and 6-carbon
cleavage metabolite in rat after oral administration. The removal of an
even number of carbon fragments has been shown to result in
-oxidation in the metabolic pathways of these compounds (Harvey and
Leuschner, 1985
; Sinz et al., 1997
). But the mechanism for removal of
an odd number of carbon fragments still remains to be fully determined.
The degraded metabolites with removal of an odd number of carbon
fragments may possibly arise from pathways other than classical
-oxidation, and the metabolic routes may involve intermediates
derived from monohydroxylation and dihydroxylation of the side chain
(Harvey, 1989
; Samara et al., 1990
; Woolf et al., 1990
). Analogous with the production mechanism of C-C bond cleavage metabolites of
olanexidine, oxidative C-C bond cleavage by cytochrome P450s may be
essential for the removal of an odd number of carbon fragments in the
metabolism of these compounds.
In summary, the present in vitro study demonstrates that the metabolic
C-C bond cleavage of the octyl side chain of olanexidine is catalyzed
by male dog liver microsomes with possible involvement of the CYP2D
subfamily. Such aliphatic C-C bond cleavage by cytochrome P450s could
play an important role in the metabolism of other drugs or endogenous
compounds containing aliphatic chains.
Received June 26, 2000; accepted August 30, 2000.
Abbreviations used are:
DM-210, 6-[5-(3,4-dichlorobenzyl)-1-biguanidino] hexanoic acid;
DM-212, 4-[5-(3,4-dichlorobenzyl)-1-biguanidino] butanoic acid;
DM-213, 5-[5-(3,4-dichlorobenzyl)-1-biguanidino] pentanoic acid;
DM-215, 8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2-octanol;
DM-218, 8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-3-octanol;
DM-217, 8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-4-octanol;
DM-221, threo-8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2,3-octandiol;
DM-222, erythro-8-[5-(3,4-dichlorobenzyl)-1-biguanidino]-2,3-octandiol;
LC/ESI-MS/MS, liquid chromatography/electrospray ionization-tandem mass
spectrometry;
CYP, cytochrome P450.